Faculty
 Program Chair:
Ramaswamy Govindan, MD
Associate Professor of Medicine, Division of Oncology
Washington University School of Medicine
St. Louis, MO
 John L. Marshall, MD
Chief, Division of Hematology and Oncology,
Lombardi Comprehensive Cancer Center, Georgetown University,
Washington, DC
Learning Objectives
After completing this activity, participants should be able to:
-
Identify and interpret leading-edge cancer research that will impact the treatment of patients
-
Recognize how published results apply to clinical practice
-
Implement strategies based on retained knowledge to optimize patient care
Target Audience
This continuing medical education activity is intended for oncologists, radiologists, gynecological oncologists, surgeons, and other medical professionals involved in the care of lung and colorectal cancer patients.
Estimated Time to Complete
The activity in its entirety should take approximately 30 minutes to complete. Participants will have the opportunity to earn 0.5 AMA PRA Category 1 Credits™ at the completion of the CME activity.
Supporter Statement
This activity is supported by an educational grant from Genentech BioOncology.
Sponsored by
 |
Parts 1-5 of the Solid Tumor 5-Minute Update series are located in the content section for this activity. Please click ‘Continue’ above and select the 5-Minute Update you would like to watch from the list under the video player on the next page.
Needs Assessment
There has been an enormous information explosion in oncology over the past few years due to the advances in the development of novel agents, and a better understanding of molecular pathogenesis of cancer. The amount of new information available is simply overwhelming, even for the committed academic oncologist focusing on one tumor type. It is even more difficult for the community-oncologist to keep up with the simultaneous advances in various fronts of a wide variety of cancers.
CME LLC has collaborated with a team of oncology specialists who have summarized recent advances that are pertinent for oncology practice, and provided a seasoned and practical perspective that may advance patient care.
Compliance Statement
This activity is an independent educational activity under the direction of CME LLC. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.
Accreditation Statement
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
CME LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty Disclosures
Dr. Govindan is a speaker for Eli Lilly and Company and Genentech, Inc.; and serves as a consultant for ImClone Systems Incorporated and Pfizer Inc.
Dr. Marshall is a speaker and advisor for, and receives research support from, Amgen Inc., Eli Lilly and Company, Hoffmann-La Roche Inc., Genentech, Inc., Pfizer Inc., and sanofi-aventis U.S.
This activity has been independently reviewed for balance.
Disclaimer
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own and do not necessarily reflect the views of the sponsor or supporter. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the faculty or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources.
Method of Participation
Starting in July and running through November 2009, participants will receive an announcement for the 5-Minute Solid Tumor Update via e-mail each month. Each announcement will include a link highlighting the new five-minute webcast presentation that summarizes recent advances in lung or colorectal cancer. Participants are required to view all five webcast presentations to be eligible to take the CME posttest. Successful completion of the posttest with a passing score of 80% or better earns the participant up to 0.5 CME credits.
Contact Information
We would like to hear your comments regarding this or other programs provided by CME LLC. In addition, suggestions for future programming are welcome. Contact us at:
Director, Continuing Medical Education
CME LLC
Harborside Financial Center
Plaza 3, Suite 806
Jersey City, NJ 07311
Phone: 800-447-4474
Fax: 201-946-0700
customer.service@cmellc.com |